MAPRE1

Across TCGA pan-cancer cohorts, MAPRE1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAPRE1 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MAPRE1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MAPRE1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, GBM, and OV are the cancer types where MAPRE1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.985	0.824	.018	12	view →
GBM	OS	Median	All	0.619	0.904	.001	6	view →
OV	DFS	Median	All	0.871	1.000	.042	4	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →
CCRCC	DFS	Quartile	All	0.490	0.965	.019	2	view →
LSCC	DFS	Quartile	II,III,IV	0.925	0.646	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAPRE1–PDAC (OS)

Open the PDAC breakdown →